Literature DB >> 19058085

Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol.

Kenichiro Yasutake1, Makoto Nakamuta, Yuki Shima, Akiko Ohyama, Kaori Masuda, Noriko Haruta, Tatsuya Fujino, Yoko Aoyagi, Kunitaka Fukuizumi, Tsuyoshi Yoshimoto, Ryosuke Takemoto, Toshihiko Miyahara, Naohiko Harada, Fukuko Hayata, Manabu Nakashima, Munechika Enjoji.   

Abstract

OBJECTIVE: The onset and progression of non-alcoholic fatty liver disease (NAFLD) seem to be affected by nutritive intake; however, detailed examinations have not been performed in non-obese NAFLD patients. The purpose of this study was to identify potential nutritive factors that affect NAFLD and its related nutritional problems.
MATERIAL AND METHODS: We investigated the distribution of abdominal fat, dietary intake, and biochemical data in patients with NAFLD and compared non-obese with obese patients.
RESULTS: There was no significant difference in the percentage of patients with diabetes or dyslipidemia between the obese and non-obese groups. Waist circumference, total abdominal fat levels, and subcutaneous fat levels were significantly higher in the obese group, while visceral fat levels were not significantly different between the two groups. Immunoreactive insulin (IRI) and homeostasis model assessment-insulin resistance (HOMA-IR) were significantly lower in the non-obese group, suggesting that the non-obese patients were not overtly insulin resistant. Although serum adiponectin and TNF-alpha levels were similar in both groups, leptin levels were significantly higher in the obese group. Total energy and carbohydrate intake tended to be higher in the obese group. A characteristic feature was that dietary cholesterol intake was significantly higher, while the intake of polyunsaturated fatty acids (PUFAs) was significantly lower in the non-obese group.
CONCLUSIONS: In non-obese NAFLD patients: 1) although visceral fat was increased, insulin resistance and/or dysregulated secretion of adipocytokines was not necessarily shown; 2) intakes of total energy and carbohydrates were not excessive, although dietary cholesterol was superabundant and dietary PUFAs were significantly lower compared with those in obese patients; and 3) characteristic fat intake may be associated with the formation of NAFLD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19058085     DOI: 10.1080/00365520802588133

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  69 in total

Review 1.  Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.

Authors:  G Musso; M Cassader; F Rosina; R Gambino
Journal:  Diabetologia       Date:  2012-01-27       Impact factor: 10.122

2.  Diet Associations With Nonalcoholic Fatty Liver Disease in an Ethnically Diverse Population: The Multiethnic Cohort.

Authors:  Mazen Noureddin; Shira Zelber-Sagi; Lynne R Wilkens; Jacqueline Porcel; Carol J Boushey; Loïc Le Marchand; Hugo R Rosen; Veronica Wendy Setiawan
Journal:  Hepatology       Date:  2020-02-14       Impact factor: 17.425

Review 3.  Management of NAFLD: a stage-based approach.

Authors:  Mary E Rinella; Arun J Sanyal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-24       Impact factor: 46.802

Review 4.  Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease?

Authors:  Munechika Enjoji; Makoto Nakamuta
Journal:  World J Gastroenterol       Date:  2010-02-21       Impact factor: 5.742

5.  Ezetimibe in the balance: can cholesterol-lowering drugs alone be an effective therapy for NAFLD?

Authors:  Giovanni Musso
Journal:  Diabetologia       Date:  2014-02-20       Impact factor: 10.122

Review 6.  Dietary habits and behaviors associated with nonalcoholic fatty liver disease.

Authors:  Kenichiro Yasutake; Motoyuki Kohjima; Kazuhiro Kotoh; Manabu Nakashima; Makoto Nakamuta; Munechika Enjoji
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 7.  Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.

Authors:  Alessandro Federico; Claudio Zulli; Ilario de Sio; Anna Del Prete; Marcello Dallio; Mario Masarone; Carmela Loguercio
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 8.  Is hepatic lipogenesis fundamental for NAFLD/NASH? A focus on the nuclear receptor coactivator PGC-1β.

Authors:  Simon Ducheix; Maria Carmela Vegliante; Gaetano Villani; Nicola Napoli; Carlo Sabbà; Antonio Moschetta
Journal:  Cell Mol Life Sci       Date:  2016-08-13       Impact factor: 9.261

9.  Impact of dietary fat on the development of non-alcoholic fatty liver disease in Ldlr-/- mice.

Authors:  Donald B Jump; Christopher M Depner; Sasmita Tripathy; Kelli A Lytle
Journal:  Proc Nutr Soc       Date:  2015-08-18       Impact factor: 6.297

10.  NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease.

Authors:  Munechika Enjoji; Kazuyuki Machida; Motoyuki Kohjima; Masaki Kato; Kazuhiro Kotoh; Kazuhisa Matsunaga; Manabu Nakashima; Makoto Nakamuta
Journal:  Lipids Health Dis       Date:  2010-03-12       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.